Catalyst

Slingshot members are tracking this event:

Based on Phase 3 trial results, Vertex Pharmaceuticals expects to submit an NDA for ORKAMBI as a treatment for cystic fibrosis in patients aged 2-5 with two copies of the F508del mutation in their CFTR gene, in Q1 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
VRTX

100%
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Orkambi, Cystic Fibrosis, Cftr